Vertex Pharmaceuticals Incorporated
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Vertex Pharmaceuticals Incorporated - overview
Established
1989
Location
Boston, MA, US
Primary Industry
Biotechnology
About
Vertex Pharmaceuticals Incorporated, based in the US, focuses on the development and commercialization of innovative medicines, particularly for serious diseases such as cystic fibrosis, sickle cell disease, and beta-thalassemia. Vertex Pharmaceuticals, founded in 1989 in Boston, US, specializes in the discovery and commercialization of therapies for serious diseases. The company has undergone strategic changes to focus on rare diseases and has no known parent or subsidiary relationships. Souzan Yanni is a key figure in the company's founding.
Vertex has raised a total of USD 2. 40 mn through various funding rounds, with the most recent round occurring on March 3, 2009. Vertex Pharmaceuticals is committed to the discovery, development, and commercialization of innovative medicines aimed at treating serious diseases. It is particularly recognized for its advancements in cystic fibrosis therapies, including CFTR modulators like Trikafta, Kalydeco, and Orkambi, which improve lung function and digestive health.
Vertex's products are marketed to healthcare providers and specialty pharmacies across North America, Europe, and parts of Asia, addressing critical medical needs for patients with cystic fibrosis and other serious conditions. In the most recent year, Vertex Pharmaceuticals reported a revenue of USD 11,020. 10 mn for 2024, with an EBITDA of USD -25. 70 mn.
The company's revenue model is based on the sales of its innovative medicines, which are primarily sold through specialty pharmacies and hospitals, and includes reimbursement agreements with insurance providers. Vertex Pharmaceuticals aims to continue expanding its product offerings, particularly focusing on the development of new therapies for cystic fibrosis and other rare diseases. The company plans to enter new geographic markets, although specific regions and timelines for expansion have not been disclosed. The capital raised in March 2009, amounting to USD 2.
40 mn, is expected to support these initiatives, enhancing Vertex's capability to address unmet medical needs and broaden its treatment portfolio.
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Epidemiology, Pharmaceutical Research & Development
Website
www.vrtx.com
Verticals
HealthTech
Total Amount Raised
Subscriber access only
Vertex Pharmaceuticals Incorporated - timeline of key events
Vertex Pharmaceuticals Incorporated - financials
| Fiscal Year Ended | Dec 31, 2008 | Dec 31, 2009 | Dec 31, 2010 | Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 175,500,000 | 101,900,000 | 143,400,000 | 1,410,600,000 | - | 1,211,975,000 | 580,415,000 | 1,032,336,000 | 1,702,177,000 | 2,488,652,000 | 3,047,597,000 | 4,162,821,000 | 6,205,683,000 | 7,574,400,000 | 8,930,700,000 | - | - | - |
| % Revenue Growth (YoY) | - | (41.9%) | 40.7% | 883.7% | - | - | (52.1%) | 77.9% | 64.9% | 46.2% | 22.5% | 36.6% | 49.1% | 22.1% | 17.9% | - | - | - |
| EBITDA (USD) | (414,200,000) | (598,900,000) | (704,900,000) | 133,200,000 | - | (855,083,000) | (629,155,000) | (404,536,000) | 71,334,000 | 184,640,000 | 707,570,000 | 1,304,507,000 | 2,965,805,000 | 2,907,700,000 | 4,455,700,000 | - | - | - |
| Operating Income (USD) | (446,400,000) | (629,000,000) | (735,400,000) | 98,100,000 | - | (903,448,000) | (692,412,000) | (466,879,000) | 9,936,000 | 123,243,000 | 635,150,000 | 1,197,566,000 | 2,856,290,000 | 2,782,100,000 | 4,307,400,000 | - | - | - |
| Operating Margin | (254.4%) | (617.3%) | (512.8%) | 7.0% | - | (74.5%) | (119.3%) | (45.2%) | 0.6% | 5.0% | 20.8% | 28.8% | 46.0% | 36.7% | 48.2% | - | - | - |
| % EBITDA Margin | (236.0%) | (587.7%) | (491.6%) | 9.4% | - | (70.6%) | (108.4%) | (39.2%) | 4.2% | 7.4% | 23.2% | 31.3% | 47.8% | 38.4% | 49.9% | - | - | - |
| NET Income (USD) | (459,900,000) | (642,200,000) | (754,600,000) | 41,200,000 | - | (687,550,000) | (742,745,000) | (588,181,000) | (84,031,000) | 91,635,000 | 2,087,103,000 | 1,176,810,000 | 2,711,647,000 | 2,342,100,000 | 3,322,000,000 | - | - | - |
| % Net Margin | (262.1%) | (630.2%) | (526.2%) | 2.9% | - | (56.7%) | (128.0%) | (57.0%) | (4.9%) | 3.7% | 68.5% | 28.3% | 43.7% | 30.9% | 37.2% | - | - | - |
Vertex Pharmaceuticals Incorporated - employee data
Vertex Pharmaceuticals Incorporated - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| Chairman of the Board | BM | ||||||
| Board Member, Former Chairman and CEO | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.